Dellas A, Torhorst J, Bachmann F, Bänziger R, Schultheiss E, Burger M M
Department of Gynecology and Obstetrics, University of Basel, Switzerland.
Cancer. 1998 Oct 1;83(7):1376-83. doi: 10.1002/(sici)1097-0142(19981001)83:7<1376::aid-cncr15>3.0.co;2-1.
A recently cloned novel p150 protein was found to be overexpressed in human breast carcinoma. To the authors' knowledge, no data on p150 expression in any other human tumors have been published previously.
To investigate whether the expression of p150 correlated with the clinicopathologic stages of cervical neoplasms or the prognoses of patients with these neoplasms, the authors conducted an immunohistochemical study of archival formalin fixed, paraffin embedded specimens. Seventy-two precancerous lesions (CIN), 75 clinical Stage IB invasive squamous carcinomas, and 20 samples of normal squamous epithelia were included. In addition to p150, the Ki-67 labeling index was assessed as a proliferation parameter. The presence of human papillomavirus was analyzed by in situ DNA hybridization.
A significant association of p150 with the grade of atypia in cervical neoplasms was demonstrated. The highest expression of p150 was observed in low grade CIN, with subsequently decreasing expression in high grade CIN and invasive carcinoma. For patients with invasive carcinoma, p150 was significantly correlated with clinical outcome. Patients with high expression of p150 had a better prognosis than those with low p150. Those with regional lymph node metastasis and significant p150 expression had longer relapse free survival than those with insignificant p150 expression. Women whose carcinomas demonstrated vascular space invasion or high microvessel density survived longer when p150 was clearly expressed. p150 behaves as a potential tumor marker during early cervical carcinoma development and is later turned off as cells proceed to more advanced stages of their malignant phenotypes.
p150 is a molecular parameter that might become useful in predicting disease progression and determining the prognoses of patients with invasive cervical carcinoma.
最近克隆出的一种新型p150蛋白在人类乳腺癌中过度表达。据作者所知，此前尚无关于p150在任何其他人类肿瘤中表达情况的数据。
为研究p150的表达是否与宫颈肿瘤的临床病理分期或这些肿瘤患者的预后相关，作者对存档的经福尔马林固定、石蜡包埋的标本进行了免疫组织化学研究。纳入了72例癌前病变（CIN）、75例临床ⅠB期浸润性鳞状细胞癌以及20例正常鳞状上皮样本。除p150外，Ki-67标记指数作为增殖参数进行评估。通过原位DNA杂交分析人乳头瘤病毒的存在情况。
证实p150与宫颈肿瘤的异型程度存在显著关联。在低级别CIN中观察到p150的表达最高，随后在高级别CIN和浸润癌中表达逐渐降低。对于浸润癌患者，p150与临床结局显著相关。p150高表达的患者预后优于p150低表达的患者。有区域淋巴结转移且p150表达显著的患者无复发生存期长于p150表达不显著的患者。癌组织显示有血管间隙浸润或微血管密度高的女性，当p150明显表达时生存期更长。在宫颈癌早期发展过程中，p150表现为一种潜在的肿瘤标志物，而随着细胞发展至恶性表型的更晚期阶段，它会被关闭。
p150是一个分子参数，可能有助于预测疾病进展并确定浸润性宫颈癌患者的预后。
